Skip to content
CancerIndex

Publication

EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Ananth Shankar, Judith Landman-Parker, Maurizio Mascarin, Andishe Attarbaschi, Sabah Boudjemaa, Roberta Burnelli, Auke Beishuizen, Michaela Cepelova, Francesco Ceppi, Thomas Georgi, Georgina Hall, Wolfram Klapper, Regine Kluge, Egesta Lopci, Monika L Metzger, Alan Ramsay, Jonas Steglich, Dietrich Stoevesandt, Lars Kurch, Dieter Körholz, Dirk Hasenclever, Christine Mauz-Körholz

Blood advancesSep 8, 2026PMID 42234940doi:10.1182/bloodadvances.2026019765 PMC13544184Clinical Trial, Phase IIIJournal ArticleMulticenter StudypubmedProvenance
Source
PubMed
Retrieved
Sep 29, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260929-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Children and adolescents with early-stage nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) have a 5-year event-free survival (EFS) of ∼77% after complete lymph node resection and ∼89% with anthracycline-containing chemotherapy. We investigated whether those patients can be successfully…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.